

The nucleotide sequence of the gene for human protein C

(DNA sequence analysis/vitamin K-dependent proteins/blood coagulation)

DONALD C. FOSTER, SHINJI YOSHITAKE, AND EARL W. DAVIE

Department of Biochemistry, University of Washington, Seattle, WA 98195

Contributed by Earl W. Davie, April 9, 1985

ABSTRACT A human genomic DNA library was screened for the gene for protein C by using a cDNA probe coding for the human protein. Three different overlapping λ Charon 4A phage were isolated that contain inserts for the gene for protein C. The complete sequence of the gene was determined by the dideoxy method and shown to span about 11 kilobases of DNA. The coding and 3' noncoding portion of the gene consists of eight exons and seven introns. The eight exons code for a preproleader sequence of 42 amino acids, a light chain of 155 amino acids, a connecting dipeptide of Lys-Arg, and a heavy chain of 262 amino acids. The preproleader sequence and the connecting dipeptide are removed during processing, resulting in the mature protein composed of a heavy and a light chain held together by a disulfide bond. The heavy chain also contains the catalytic region for the serine protease. Two *Alu* sequences and two homologous repeats of about 160 nucleotides were found in intron E. The seven introns in the gene for protein C are located in essentially the same positions in the amino acid sequence as the seven introns in the gene for human factor IX, while the first three introns in protein C are located in the same positions as the first three in the gene for human prothrombin.

Protein C is a precursor to a serine protease present in plasma that plays an important physiological role in the regulation of blood coagulation (1, 2). Human protein C is a vitamin K-dependent glycoprotein containing nine residues of γ -carboxyglutamic acid and one equivalent of β -hydroxy-aspartic acid. Protein C shows considerable structural homology with the other vitamin K-dependent plasma proteins involved in blood coagulation, including prothrombin, factor VII, factor IX, and factor X. Protein C is synthesized as a single-chain polypeptide that undergoes considerable processing to give rise to a two-chain molecule held together by a disulfide bond. The two-chain form is converted to activated protein C by thrombin by the cleavage of a 12-residue peptide from the amino terminus of the heavy chain (2). This reaction is greatly accelerated by the presence of thrombomodulin (3). Activated protein C regulates the coagulation process by the inactivation of factor V_a (4, 5) and factor VIII_a (4, 6) by minor proteolysis. Consequently, individuals lacking protein C often have a history of thrombotic disease (7, 8).

Studies from our laboratory (9) and that of others (10) have led to the isolation and characterization of the cDNA coding for human and bovine protein C. In the present investigation, the cDNA for human protein C has been used for the isolation of overlapping genomic clones from a λ Charon 4A phage library. The nucleotide sequence of the gene was then determined and compared with the genes for human factor IX (11, 12) and prothrombin (13).

MATERIALS AND METHODS

Screening of the Genomic Library. A human genomic library in λ Charon 4A phage (14) was screened for genomic clones of human protein C by the plaque hybridization procedure of Benton and Davis as modified by Woo (15) using a cDNA for human protein C (9) as the hybridization probe. The cDNA started at amino acid 64 of human protein C and extended to the second polyadenylation signal (9). It was radiolabeled by nick-translation to a specific activity of 8×10^8 cpm/ μ g with all four radioactive ($[\alpha\text{-}^{32}\text{P}]\text{dNTP}$) deoxynucleotides. The probe was denatured and hybridized to the filters at a concentration of 1×10^6 cpm/ml in a hybridization solution containing $6\times$ NaCl/P_i ($1\times$ NaCl/P_i = 0.15 M NaCl/0.015 M sodium citrate, pH 7.0), $5\times$ Denhardt's solution ($1\times$ = 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin), 0.1% sodium dodecyl sulfate, 100 μ g of yeast tRNA per ml, and 50% formamide at 42°C for 60 hr. The filters were washed in $1\times$ NaCl/P_i containing 0.1% sodium dodecyl sulfate at 68°C for 1 hr and exposed to x-ray film for 16 hr. Positive clones were then isolated and plaque-purified.

DNA Sequence Analysis. Phage DNA was prepared from positive clones by the liquid culture lysis method as described by Silhavy *et al.* (16). The genomic DNA inserts in the purified phage were removed by digestion with *Eco*RI and then subcloned into pUC9 for subsequent restriction mapping and sequencing. In order to obtain overlapping DNA fragments, the DNA inserts were digested also with *Bgl* II, and the fragments corresponding to the gene for protein C were subcloned into the *Bam*HI site of pUC9.

The sequence of genomic fragments containing the gene for protein C was determined both by direct cloning of specific restriction fragments into the M13 phage cloning vectors mp10, mp11, mp18, and mp19, as well as by the BAL-31 exonuclease method described by Guo *et al.* (17) and Yoshitake *et al.* (12).

Dideoxy chain termination sequencing reactions were carried out with ^{35}S -substituted deoxyadenosine 5'- $[\alpha\text{-thio}]\text{triphosphate}$ (dATP $[\alpha\text{-}^{35}\text{S}]$; Amersham) essentially as described in the sequencing manual provided by Amersham and run on buffer gradient gels as described by Biggin *et al.* (18). More than 90% of the sequence was determined two or more times, and $\approx 50\%$ was determined on both strands. DNA sequences were stored and analyzed by the computer programs of Larson and Messing (19).

M13 vectors mp10, mp11, mp18, and mp19, deoxynucleotide triphosphates, and dideoxynucleotide triphosphates were purchased from P-L Biochemicals. Restriction enzymes, T4 DNA ligase, bacterial alkaline phosphatase, and the *Escherichia coli* DNA polymerase I (Klenow fragment) were purchased from New England Biolabs or from Bethesda Research Laboratories.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviation: kb, kilobase(s).




FIG. 1. Detailed restriction map and sequencing strategy for the gene for human protein C. The locations of each of the eight exons are shown with solid bars. The length and direction of each sequencing reaction are shown by thin arrows.

RESULTS AND DISCUSSION

A human genomic DNA library (2×10^6 phage) in λ Charon 4A phage was screened with a radiolabeled cDNA probe for human protein C. Three different positive clones were isolated, and each was plaque-purified. These three clones exhibited unique patterns of *EcoRI* fragments upon electrophoresis in 0.7% agarose but also contained fragments in common with each other. Southern blot hybridization of digests of these clones with probes made from the 5' and 3' ends of the cDNA established that one of the clones (PC λ 1) corresponded to the 5' region of the gene for protein C,

another (PC λ 8) to the 3' region, and the third (PC λ 6) was positive to both sets of probes.

The genomic DNA inserts in PC λ 6 and PC λ 8 were mapped by single- and double-restriction-enzyme digestion followed by agarose gel electrophoresis, Southern blotting, and hybridization to radiolabeled 5' and 3' probes derived from the cDNA for human protein C. This analysis suggested that the gene for protein C was present in three *EcoRI* fragments of 4.4, 6.2, and 6.9 kilobases (kb) oriented 5' to 3' in the genome. The 4.4-kb fragment was isolated from phage PC λ 6, and the 6.2-kb and 6.9-kb fragments were isolated from phage PC λ 8; each was subcloned into the *EcoRI* site of pUC9. To provide

AGTGAATCTG	GGCAGTAAC	ACAAAACCTG	AGTGTCTTA	CCTGAAAAAT	AGAGGTAGA	GGGATGCTAT	GTGCCATTGT	GTGTGTGTGT	TGGGGTGGG	GATTGGGGT	GATTGTGAG	CAATTGGAGG	-2001	
TGAGGGTGA	GCCAGTGCC	CAGCACCTAT	GCACCTGGGA	CCCAAAAAGG	AGCATCTCT	CATGATTTTA	TGATCAGAA	ATTGGGATG	CATGTCTTG	GGACAGCTC	TTTTTCTTG	TATGGTGGCA	-1871	
CATAAATACA	TGTGCTTAT	AATTAATGGT	ATTTTAGATT	TGACGAAATA	TGGAATATTA	CCTGTTGTGC	TGATCTTGG	CAAACTATA	TATCTCTGG	CAAAAATGC	CCCATCTGAA	AAACAGGGAC	-1741	
AACGTTCCCT	CCTCAGCCAG	CCACTATGGG	GCTAAAATGA	GACCACATCT	GTCAAGGGTT	TTGCCCTCAC	CTCCCTCCCT	GCTGGATGG	ATCCTTGTA	GGCAGAGGTG	GGCTTCGGGC	AGAAACAGCC	-1611	
GTCGTAGCT	AGGACCCAGG	GTCTAGTGC	CACCTGTGAT	CTATGGAGAG	GGAGGCTCA	GTGCTAGGG	CCAAGCAAT	ATTTGTGGT	ATGGATTAA	TGCACTCCA	GGCTGTCTG	CGCCAGGAC	-1481	
GGCGAACTTG	CAGTATCTCC	ACGACCCCGG	CCCTGTGATC	CCCTCCAGG	CAGGTCATG	AGGGGTGTGG	CCAGGCAAT	GGCCCCGGG	GAAGAGAGCT	AGGCTGTGAT	GAGGGCTGAA	TCCTCCAGCC	-1351	
AGGGTGCTCA	ACAAGCTGA	GCTTGGGGTA	AAAGGACACA	AGGCCCTCCA	CAGGCCAGCC	CTGGCAGCCA	CAGTCTCAG	TCCTTTGGC	ATGCGCTCC	CTCTTCCAG	GCCAAGGGTC	CCAGGCCCA	-1221	
GGGCCATTCC	ACACAGAGT	TTGGAGCCCA	GGACCTCCA	CCCACTTCCA	CCTTTGGGGG	GTCTCGATTT	GGTCCGATTT	GAACAATCT	CAGAAGCGCC	CTCAGAGGGA	GTCCGCAAGA	ATGGAGAGCA	-1091	
GGTCCGGTA	GGGTGTGAG	AGGCCACGTG	GCCTATCCAC	TGGGGAGGGT	TCCTTGATCT	CTGGCCACCA	GGGCTATCT	TGTGCCCTT	TGGAGCAAC	TGTTGGTTG	GGCAGGGGT	TGAATTTCA	-961	
GGCCTAAAAC	CACACAGGCC	TGGCCTTGAG	TCCTGGCTCT	CGCAGTAATG	CATGGATGTA	AACATGGAGA	CCAGGACCT	TGCCCTAGT	TTCCGAGTC	GGTGCCTGA	GTGTACTGAT	GGTGTGAGC	-831	
CCTACTCCTG	AAGATGGTGG	GACAGAACT	GATCGATCCC	CTGGTGTGGT	GACTTCCCTG	TGCAATCAAC	GGAGCACCAG	AAGGGTTGA	TTTTTAATA	ACCACCTAAC	CTCTCCGAG	CTCAGTTCT	-701	
CCCTCATGA	GATGGGGTTG	ACAGCATTAA	TAACCTACCT	TTGGTGTGGT	GTGAGCTTGA	ACTGAAGTCA	TAATATCTCA	GTGTTACTGA	GCATGAGCTA	TGTCGAAAG	CGTGTTTGAG	AGCTTTTAT	-571	
GGACTAACTC	CTTAATCTCT	CACAAACCC	TTTAAGGCCA	AGATACACCA	CGTATTCTCA	TCAATTTTAC	AAATAGGAA	ACTGAGGCA	GGAGCAGTA	AGCATCTTGC	CCACATTTGC	CTCCAGTAA	-441	
GTGCTGGAGC	TGGAATTTG	ACCGTGCAGT	CTGGCTTCAT	GGCCTGCCCT	GTGAATCTG	TGAAAGTTC	TGAAAGACA	CCATGAGTGT	CCAATCAAG	TTAGCTAAG	TTCTCAGCC	AGTCATCA	-311	
CCGGCAGAGG	CAGCCACCC	ACTGTCCCA	GGAGGACAG	AAACATCTCT	GCACCTCTG	CAGTCAATC	TGGAGTCTG	TTCTAGGCA	GCAGTGTGAG	CTCAGCCCA	CGTAGAGCC	GCAGCCGAG	-181	
CCTTCTGAGG	CTATGTCTCT	AGGGAACAAG	GACCTCCAAT	TCCAGCTTCC	GCCTGACGGC	CAGCACACAG	GGACAGCCCT	TTCACTCCG	TTCCACTGG	GGGTGCAGG	AGAGCAGCA	CGGGGTAGC	-51	
ACTGCCCGGA	GCTCAGAAGT	CCTCCTCAGA	CAGGTGCCAG	TGCCCTCAGA	ATG TGG CAG CTC ACA	AGC CTC CTG	CTG TTC GTG GCC ACC	TGG GGA ATT	TCC GGC ACA	CCA GCT			63	
Pro Leu	CCT CTT G	GTAAAGGCCAC	CCCACCCCTA	CCCCGGGACC	CTTGTGGCCT	CTACAAGGCC	CTGGTGGCAT	CTGCCCAGGC	CTTCACAGCT	TCCACCATCT	CTCTGAGCCC	TGGGTGAGGT	GAGGGGCAGA	190
TGGGAATGGC	AGGAATCAAC	TGACAAGTCC	CAGGTAGGCC	AGCTGCCAGA	GTGCCACACA	GGGGTGGCCA	GGGCAGGCAT	CGGTGATGG	AGGGAGCCCC	CGCATGACC	CCTAAAGCTC	CCCTCCTCAC	320	
ACGGGGATGG	TCACAGAGTC	CCCTGGGGCC	TCCCTCTCCA	CCCCTACTCT	CCCTCAACTG	GTGAGGCCCC	AGGGCCAGGC	TACCCCTCAC	ACTATCCAG	ACAGCCCTCC	CTACTCAAA	CCACCTCCGC	450	
CTCATGAGCT	CCCTGCCCCA	ACCCCTTTCC	TGCTCTCCAC	AGCCACAGGG	AGGAGGCCAT	GATTCCTGGG	AGGGCTCCCA	GGCATATGG	CCCTCAAGC	CACACCCAGC	TGTTGGTTTC	ATTTGTGCTC	580	
TTATAGAGCT	TGTTATCTGC	ACCTGACCTG	CACCTCTCCAG	CTTTCCCAAG	GTGCCCTCAG	CTCAGGATCA	CCCTCGATTT	GGATGCCCTT	TCCCCATCC	CTCTTGTCTC	ACACCCCAAA	ATTTGATCTC	710	
CCCTCCTAAC	TGTCCTCTGC	ACCAAGACAG	ACACTTCCAC	GAGCCCAAGG	CACACCTCCG	GACCTTCTCT	GGGTGATAGG	TCTGTCTAT	CTCCAGGTTG	CCCTGCCCAA	GGGGAGAAAG	ATGGGGAATC	840	
CCTTGTGGGG	GGAGGAAAGG	AGACTGGGG	GGATGTGTCA	AGATGGGGCT	CATCTGGTGG	ACTGAGGACA	AGAGTGAGAG	GATTTAACT	GGCAGCCTT	ACAGCAGCAG	CCAGGGCTTG	AGTACTTATC	970	
TCTGGGCCAG	GCTGTATTGG	ATGTTTTTACA	TGACGGTCTC	ATCCCATGTT	TTTTGGATGA	GTAATTTGAA	CCTTAGAAAG	GTAAGACAC	TGGCTCAAG	TCACACAGAG	ATCGGGGTGG	GGTTCCAGAG	1100	
GAGGCCCTGC	CATCTCAGAG	CAAGGCTTGC	TCTCCAAC	GCCATCTGCT	TCTTGGGGAG	GAAAAGAGCA	GAGGAGCCCT	GGCCCAAGCC	ATGACCTAGA	ATTAGAATGA	GTCTTGGAGG	GGCCGAGACA	1230	
AGACCTTCCC	AGGCTCTCCC	AGCTCTGCTT	CCTCAGACCC	CCTCATGGCC	CCAGCCCTCC	TTAGGCCCTC	CACCAAGGTG	AGCTCCCTCC	CCTCCAAAAC	CAGT AC	TCA GTG TTC	TCC AGC AGC	1353	
Glu Arg Ala His Gln Val Leu Arg Ile Arg Lys Arg Ala Asn Ser Phe Leu Glu Glu Leu Arg His Ser Ser Leu Glu Arg Glu Cys Ile Glu Glu Ile Cys Asp	GAG CGT GCC CAG CTG CGG ATC CGC AAC CGT GCC AAC TCC TTC CTG GAG GAG CTC CGT CAC	AGC AGC CTG GAG CGG GAG TGC ATA GAG GAG ATC TGT GAC											1458	
Phe Glu Glu Ala Lys Glu Ile Phe Gln Asn Val Asp Asp Thr	TTC GAG GAG GCC AAG GAA ATT TTC CAA AAT GTG GAT GAC ACA	GTAAAGGCCAC	CATGGTCCA	GAGGATGAGG	CTCAGGGGCG	AGCTGGTAAC	CAGCAGGGGC	CTCGAGGAGC						1570
AGGTGGGGAC	TCATGCTGA	GGCCCTTTA	GGAGTGTGG	GGGTGGCTGA	GTGGAGGCTA	TAGGATGCTG	CGCCATGAT	GTCCGCCAG	CACATGTGAC	TGCAGAAAC	AGAATTCAGG	AGAAGCTCC	1700	
AGGAAAGAGT	GTGGGGTGA	CCTAGGTGGG	GACTCCCA	GCCACAGTGT	AGTGTGGTTA	GTGACCCATG	CAGCCACTGT	TGAGCACCA	TGCTCCCG	TCCACCTCA	CAAGAGGGG	ACCTAAAGAC	1830	
CACCCCTGCT	CCACCATG	CTCTGCTGAT	CAGGGTGTG	GTGTGACCGA	AACCTACTCT	TGTCACATA	AAATGCTCA	CTCTGTGCT	CACATCAAG	GGAGAAATC	TGATTTGTTCA	GGGGTCCGA	1960	
AGACAGGCTG	TGTGCTGAT	TGTCTAAGG	GTCAAGTCC	TTTGGAGCCC	CCAGAGTCTC	GTGAGAGTGG	CCCTAGGTA	TAGGGTGA	TTGGTAACGG	GGCTGGCTC	CTGAGCAAG	GCTCAGACC	2090	
GCTCTGTCCC	TGGGATGCG	TTAGCCAC	AGGACCTGAA	AATTTGTGAC	GCCTGGGCC	CCTTCCAAG	CATCCAGGAG	TGCTTTCCAG	TGGAGGCTT	CAGGGCAGGA	GACCCCTCG	CCTGACCTC	2220	
CTCTTGGCCT	AGCCCTCAC	CTCCTGACT	GGACCCCAT	CTGGACCTCC	ATCCCAACCA	CCTCTTCCG	CAGTGGCCTC	CTTGGCAGC	ACCACAGTA	CTTTCTGAC	GCACATATCT	GATCAGTCA	2350	
AGTCCCAACC	GTGCTCCAC	CTACCCATG	GTCTCTCAG	CCCAGCAGCC	TTGGCTGGC	TCTCTGATGG	AGCAGCATC	AGGCACAGG	CGTGGTCTC	AACGTGGCTC	GGGTGGTCT	GGACCAGCAG	2480	
CAGCCCGCCG	AGCAGCAAC	CTGTACTCT	GTTAGGAAG	CAGACCTCT	GCCCCATCC	TCCCAACTCT	GAAAAACATC	GGCTTAGGGA	AAGGCAGAT	GCTCAGGGT	CCCCCAAGC	CCGCAGGCA	2610	
AGGGAGTAT	GGACTGGAA	GGAGGCCAG	TGACTTGGT	AGGGATTCGG	GTCCCTTGCA	TCCAGAGGCT	CGTGGGAG	CGCAGCTGC	CGAGAGCAG	ACTGCAGCC	GTTGGGGAG	GGGTGTGCT	2740	
CCAGGACGT	GGATGGAGG	CTGGGCGGG	CGGGTGGC	CTGGAGGGC	GGGGAGGGC	AGGGAGCACC	AGCTCTAGC	AGCCAACAGC	CATCGGGCT	CGATCCCTGT	TTGCTGAA	CCCTCCCT	2870	
CCCTGCCCG	CTACCCGCT	GGCTGCC	ACCCGGGCG	GGCCCTCCG	ACACCGGCTG	CAGGAGCCTG	AGCTGCCG	CTCTCCCG	AGTCTG	TTC TGG TCC	AAG CAC GTC	GTGGAGT	2993	
GCTTCTAGA	TCCCGGGT	GACTACCGG	GGCCGCGCC	CCTCGGATCT	CTGGCCGCTG	ACCCCTTACC	CGCCTTGTG	TCGCAG	AC	GGT GAC CAG TGC	TTG GTC TTG CCC	TTG GAG	3111	
His Pro Cys Ala Ser Leu Cys Cys Gly His Gly Thr Cys Ile Asp Gly Ile Gly Ser Phe Ser Cys Asp Cys Arg Ser Gly Trp Glu Gly Arg Cys Cys Gln Arg	CAC CCG TGC CGC AGC CTG TGC TGC GGG CAC GGC ACG TGC ATC GAC GGC ATC GGC AAG TCC AGC TGC	GAC TGC CGC AGC GGC TGG GAG GGC CTT GTC CAG CGC											3216	
G GTGAGGG	GGAGAGTGG	ATGCTGGCG	CGGGCGGGC	GGGGCTGGG	CCGGTGTGG	GGCCGGGCA	CAGCACCAGC	TGCCCGGCC	CTCCCTGCC	CGCAGT	AG GTG AGC TTC	CTC AAT	3336	

FIG. 2. (Figure continues on the opposite page.)




FIG. 2. Nucleotide sequence for the gene for human protein C. The first base of the methionine codon where translation is initiated is numbered +1. Arrowheads indicate intron-exon splice junctions. The two *Alu* sequences in intron E have been underlined with a solid line; the 18-base repeats flanking the first *Alu* sequence and the 8-base repeats flanking the second *Alu* sequence have been underscored with dots. The highly conserved sequences of C-C-A-G-C-C-T-G-G have been underlined with a heavy solid line, contrasting with the two homologous 160-bp repeats in intron E which have been lightly underlined. The polyadenylation or processing sequences of A-T-T-A-A-A and A-A-T-A-A-A at the 3' end are boxed. The consensus of C-T-T-T-G, which also may be involved in polyadenylation or cleavage of mRNA at the 3' end, is underlined with a wavy line. ♦, Potential carbohydrate binding sites to asparagine residues; ¶, apparent cleavage sites for processing of the connecting dipeptide; J, site of cleavage in the heavy chain when protein C is converted to activated protein C; ○, active site aspartic acid, histidine, and serine residues; ●, sites of polyadenylation.

DNA sequence overlapping the two *EcoRI* junctions between the three fragments, two *Bgl* II fragments of 3.3 and 7.0 kb were isolated and subcloned into the *Bam*HI site of pUC9. These two clones span the *EcoRI* sites.

A detailed restriction map as well as approximate placement of the exon regions within the subcloned fragments were established by further restriction analysis and Southern blotting (Fig. 1). When the 5' and 3' ends of the gene were established, the nucleotide sequence of the gene was determined by the dideoxy chain-termination method using

nuclease *BAL*-31 to provide overlapping sequences between the ends of large restriction fragments.

The nucleotide sequence for the gene for human protein C spans ≈11 kb of DNA (Fig. 2). Comparison of the genomic sequence with that of the cDNA (9) revealed that the gene consists of eight exons ranging in size from 25 to 885 nucleotides and seven introns ranging in size from 92 to 2668 nucleotides. An additional intron(s) in the 5' noncoding region cannot be ruled out because a cDNA covering this region was not available for comparison with the gene. Also,




FIG. 3. Amino acid sequence and tentative structures for human prepro-protein C and prepro-factor IX. Protein C is shown without the Lys-Arg dipeptide, which connects the light and heavy chains. Locations of the seven introns (A through G) for each gene are indicated by solid bars. Amino acids flanking known proteolytic cleavage sites are circled. The active-site histidine, aspartic acid, and serine residues are also circled. ♦, Potential carbohydrate binding sites. The proposed disulfide bonds have been placed by analogy to those in bovine prothrombin and epidermal growth factor. The first amino acids in the light chain, activation peptide, and heavy chain start with number 1 and differ from that shown in Fig. 2. The factor IX structure was that of Yoshitake *et al.* (12). γ , γ -carboxyglutamic acid; β , β -hydroxyaspartic acid.

several potential intron/exon splice donor and acceptor sequences were identified in the 5' noncoding region. All the intron/exon splice junctions were similar to the consensus sequences recently summarized by Mount (20) and follow the G-T/A-G rule of Breathnach and Chambon (21).

Several potential "TATA" sequences were found upstream from the preproleader sequence in the gene for human protein C. The sequences of T-A-T-A-A-T-A (starting at position -1785) and T-A-T-A-A-T-T (starting at position -1853) show the strongest homology with the consensus sequence of T-A-T-A-A-T-A. Both, however, lack nearby "CAAT" sequences upstream. If either of these sequences is associated with initiation of transcription, then protein C would have either a very long 5' noncoding sequence or an additional intron(s) in the 5' noncoding region of the gene.

Two polyadenylation or processing sequences of A-T-T-A-A-A and A-A-T-A-A-A (22) were found 47 and 276 nucleotides downstream from the translation stop codon (nucleotides starting at 9022 and 9251). The second of these also has a sequence of C-T-T-T-G starting 37 nucleotides downstream. This latter sequence corresponds to the C-A-T-T-G consensus sequence and also may be involved in polyadenylation or cleavage at the 3' end of the mRNA (23). The DNA sequence of eight separate cDNAs at the 3' end indicates that polyadenylation occurs with about equal frequency downstream from the two polyadenylation or processing sites (data not shown).

The gene for protein C contains two *Alu* sequences (24), and both are located in intron E (solid underline in Fig. 2). The first is a complete copy with an orientation of 3' to 5'. It is flanked by the direct repeat sequence of T-C-T-T-T-C-A-G-G-G-A-A-C-T-T-T-C-T. The second *Alu* sequence is 30 nucleotides after the flanking repeat of the first and is a partial copy of an *Alu* sequence oriented 5' to 3'. This *Alu* sequence lacks the right half of the *Alu* consensus sequence and is flanked by the direct repeat of A-A-A-A-T-T-T. Intron E also contains two direct repeats of about 160 nucleotides of

unknown significance (dashed underline in Fig. 2). These repeats are about 93% homologous and start at nucleotides 5628 and 5800. They are separated by 10 nucleotides. A computer comparison of this sequence with the National Institutes of Health sequence data bank revealed no significant homology with published sequences.

The cDNA sequence (9), along with that of the gene, provides the entire amino acid sequence for human preproprotein C (Fig. 3 *Left*). These data indicate that human protein C, like the other vitamin K-dependent coagulation factors, is initially synthesized as a single-chain precursor with a preproleader sequence of 42 amino acids. This leader sequence shows considerable amino acid sequence homology with that recently described for bovine protein C (10). Based on homology with the leader sequence of bovine protein C and other γ -carboxylated coagulation proteases in the region from -1 to -20, it is likely that this leader sequence is cleaved by a signal peptidase after the alanine residue at position -10. This would yield a prozymogen form with a highly basic propeptide of nine residues. Processing to the mature protein that circulates in plasma involves additional proteolytic cleavage after residues at -1, 155, and 157 to remove the amino-terminal propeptide and the Lys-Arg dipeptide that connects the light and heavy chains (9). The processing of the single chain is not complete, however, because about 5–15% of the protein C in human plasma is present as a single-chain molecule (25).

The amino acid composition of the mature protein C circulating in plasma was calculated as follows: Asp₂₈Asp(β OH)₁ Thr₁₅ Ser₃₀ Glu₂₄ Gln₁₃ Glu₉ Pro₁₈ Gly₃₃ Ala₂₁ Val₂₆ Met₇ Ile₁₆ Leu₄₃ Tyr₈ Phe₁₃ Lys₂₂ His₁₇ Arg₂₃ Trp₁₃ Cys₂₄, in which Glu is γ -carboxyglutamic acid and Asp(β OH) is β -hydroxyaspartic acid. The molecular weight for the protein was calculated to be 47,456 without carbohydrate and about 61,600 with the addition of 23% carbohydrate (26). Four of the potential carbohydrate chains bound to asparagine occur

at residues 97 in the light chain and at residues 79, 144, and 160 in the heavy chain (Fig. 3).

The DNA sequence of the coding region for the gene for human protein C agrees well with that of the cDNA for human protein C (9) except for the triplet coding for Asp-214. Both the genomic sequence (GAT) and the cDNA sequence (GAC) specify aspartic acid at this position. It is likely that the discrepancy is due to either polymorphism or a cloning artifact at nucleotide 7228. The genomic DNA sequence and the sequence of longer cDNA molecules have shown that the amino acid at residue 64 is cysteine rather than glutamine as previously reported (9). This discrepancy is likely to have resulted from an artifactual error introduced into the cDNA sequence adjacent to the *EcoRI* linker used in constructing the λ gt11 cDNA library. This phenomenon has been observed in several other cDNAs characterized in this laboratory (unpublished results).

Protein C shows considerable amino acid sequence and structural homology with the other vitamin K-dependent coagulation factors including prothrombin, factor VII, factor IX, and factor X. Factor IX, factor X, and protein C are unusually similar in that they have common domain structures throughout their molecules including a γ -carboxyglutamic acid domain, two potential growth factor domains, an activation peptide or connecting region, and a catalytic domain (27). In prothrombin, the potential growth factor domains have been replaced by two kringle structures. The similarity between these proteins is also evident at the level of the gene where protein C and factor IX show unusual homology. This is illustrated in Fig. 3, which shows the proposed domain structures and the seven introns in the genes for these two proteins. In both genes, the introns occur in essentially the same positions throughout the amino acid sequence of the two proteins. The similarity between these two genes is further reflected in the conservation of splice junction type. All seven introns in the gene for protein C exhibit the same splice junction type as the intron in the corresponding location in the gene for factor IX (12). However, a computer search of the DNA sequences within the introns of the genes in protein C and factor IX showed no significant homology, indicating that the sequences of these regions of the genes are not conserved during evolution.

The locations of the introns in the genes for protein C and factor IX are primarily between various functional domains of the two proteins (Fig. 3). Exon II spans the highly conserved region of the leader sequence and the γ -carboxyglutamic acid domain. Exon III includes a stretch of eight amino acids which connect the γ -carboxyglutamic acid and growth factor domains. Exons IV and V each represent a potential growth factor domain, while exon VI covers a connecting region that includes the activation peptide. Exons VII and VIII cover the catalytic domain typical of all serine proteases.

The first three introns in the gene for human prothrombin (28) also occur in the same position in the amino acid sequence as those of protein C and factor IX. In prothrombin, however, the γ -carboxyglutamic acid region is followed by two kringle structures, which are unrelated in sequence to the potential growth factor domains of protein C and factor IX. After the first three introns, there appears to be no similarity in gene structure between that of prothrombin and those of factor IX and protein C.

The alignment of intron boundaries in the genes for protein C, factor IX, and prothrombin provides additional evidence

for the evolution of these genes from a common ancestral precursor. This could have resulted from the joining of numerous fragments of similar DNA sequences by a translocation event(s) between chromosomes during evolution. This could lead to the formation of a gene coding for a serine protease containing additional domains such as the potential growth factor domains, kringle domains, and γ -carboxyglutamic acid domains (12).

The authors thank Drs. Dominic Chung, Steven Leytus, Takehiko Koide, and Kotoku Kurachi for helpful discussions and advice, and Dr. Tom Maniatis for kindly providing the human genomic library constructed in λ Charon 4A bacteriophage. This work was supported in part by a research grant (HL 16919) from the National Institutes of Health. D.C.F. was supported by National Institutes of Health Training Grant GM 07270.

1. Stenflo, J. (1976) *J. Biol. Chem.* **251**, 355–363.
2. Kisiel, W., Ericsson, L. H. & Davie, E. W. (1976) *Biochemistry* **15**, 4893–4900.
3. Esmon, C. T. & Owen, W. G. (1981) *Proc. Natl. Acad. Sci. USA* **78**, 2249–2252.
4. Kisiel, W., Canfield, W. M., Ericsson, L. H. & Davie, E. W. (1977) *Biochemistry* **16**, 5824–5831.
5. Marlar, R. A., Kleiss, A. J. & Griffin, J. (1982) *Blood* **59**, 1067–1072.
6. Vehar, G. A. & Davie, E. W. (1980) *Biochemistry* **19**, 401–410.
7. Griffin, J. H., Evatt, B., Zimmerman, T. S., Kleiss, A. J. & Wideman, C. (1981) *J. Clin. Invest.* **68**, 1370–1373.
8. Griffin, J. H., Mosher, D. F., Zimmerman, T. S. & Kleiss, A. J. (1982) *Blood* **60**, 261–264.
9. Foster, D. & Davie, E. W. (1984) *Proc. Natl. Acad. Sci. USA* **81**, 4766–4770.
10. Long, G. L., Belagaje, R. M. & MacGillivray, R. T. A. (1984) *Proc. Natl. Acad. Sci. USA* **81**, 5653–5656.
11. Anson, D. S., Choo, K. H., Rees, D. J. G., Giannell, F., Gould, J. A., Huddleston, J. A. & Brownlee, G. G. (1984) *EMBO J.* **3**, 1053–1060.
12. Yoshitake, S., Schach, B. G., Foster, D. C., Davie, E. W. & Kurachi, K. (1985) *Biochemistry*, in press.
13. Degen, S. J. F., MacGillivray, R. T. A. & Davie, E. W. (1983) *Biochemistry* **22**, 2087–2097.
14. Maniatis, T., Hardison, R. C., Lacy, E., Lauer, J., O'Connell, C., Quon, D., Sim, G. K. & Efstratiadis, A. (1978) *Cell* **15**, 687–702.
15. Woo, S. L. C. (1979) *Methods Enzymol.* **68**, 381–395.
16. Silhavy, T. J., Berman, W. L. & Enquist, L. W. (1984) *Experiments with Gene Fusions* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), pp. 140–141.
17. Guo, L. H., Yang, R. C. A. & Wu, R. (1983) *Nucleic Acids Res.* **11**, 5521–5540.
18. Biggin, M. D., Gibson, T. J. & Hong, G. F. (1983) *Proc. Natl. Acad. Sci. USA* **80**, 3963–3965.
19. Larson, R. & Messing, J. (1982) *Nucleic Acids Res.* **10**, 39–50.
20. Mount, S. M. (1982) *Nucleic Acids Res.* **10**, 459–472.
21. Breathnach, R. & Chambon, P. (1981) *Annu. Rev. Biochem.* **50**, 349–383.
22. Proudfoot, N. & Brownlee, G. (1981) *Nature (London)* **252**, 359–362.
23. Berget, S. M. (1984) *Nature (London)* **309**, 179–181.
24. Deininger, P. L., Jolly, D. J., Rubin, C. M., Freidmann, T. & Schmid, C. W. (1981) *J. Mol. Biol.* **151**, 17–33.
25. Miletich, J. P., Leykam, F. J. & Broze, G. J. (1983) *Blood Suppl.* **1**, 62, 306a.
26. Kisiel, W. & Davie, E. W. (1981) *Methods Enzymol.* **80**, 320–332.
27. Banyai, L., Varadi, A. & Patthy, L. (1983) *FEBS Lett.* **163**, 37–41.
28. Davie, E. W., Degen, S. J. F., Yoshitake, S. & Kurachi, K. (1983) *Dev. Biochem.* **25**, 45–52.